SNN changes
Pick any two versions below to diff them.
- Price
- $29.06 → $29.23(+0.6%)
- Discount
- 15% to 31% → 14% to 30%(−1.0 pts)
- Recent events
- 2026-10-08: Smith+Nephew said it will publish its Q3 2026 trading report on November 4, 2026. 2026-09-22: Smith+Nephew received FDA 510(k) clearance for its LANDMARK Total Knee System, and surgeons completed the first cases. It plans a phased launch, with broader availability across markets during 2027. 2026-09-18: Smith+Nephew said it will redeem its $350 million of 5.150% notes due 2027. On September 16, 2026, it announced the results of a cash tender offer for up to $250 million of its 2.032% notes due 2030. 2026-09-10: Smith+Nephew priced an issue of $700 million of 5.750% notes due 2036. 2026-08-19: Smith+Nephew said that CFO John Rogers will leave on September 30, 2026, to take an external position in the U.S. He stepped down from the board at once, and the company started a search for his successor. Pierre Palassian, Senior Vice President Finance and Group Controller, is interim CFO until the company appoints a successor. 2026-08-04: Smith+Nephew reported Q2 and first half 2026 results. Q2 revenue was $1,597 million, with underlying growth of 1.6%. First half trading profit rose 8.1% to $566 million and adjusted EPS rose 11.0% to 47.7 cents. The company cut its 2026 revenue growth outlook to about 4% from about 6%, but kept its guidance for about 8% trading profit growth and about $800 million of free cash flow. The interim dividend rose 4.0% to 15.6 cents. 2026-05-06: Smith+Nephew started a $500 million share buyback program. By August 3, 2026, $216 million of it was settled.